MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

NCT03062397 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2019-11-18

No results posted yet for this study

Summary

Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

JPI-289 Low-dose

JPI-289 Low dose will be intravenously administered during 24 hours

DRUG

JPI-289 High-dose

JPI-289 High dose will be intravenously administered during 24 hours

DRUG

Placebo

Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours

Sponsors & Collaborators

  • Jeil Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-09
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062397 on ClinicalTrials.gov